October 31, 2022

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

WEEKLY HIGHLIGHT

NRG Cancer Care Delivery Research (CCDR) Committee Hosts Webinar on Artificial Intelligence 





See flyer here

 

Register here

 

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Actively Recruiting MALE Patients only. Read More

 

2. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Memo (dated October 25, 2022) and Summary Sheet regarding new participant-directed materials (posted on CTSU).


3 GENITOURINARY

NRG-GU010: Patient Recruitment Videos, video scripts and CIRB approvals posted to CTSU and NRG Oncology.

 

4. GYNECOLOGIC

GOG-0210: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.


GOG-0225: To provide the most accurate and reliable assessment possible, sites are asked to answer any outstanding queries and update the Overall Survival status and last contact date for all patients enrolled on GOG-0225 no later than Friday, December 2, 2022. This trial utilizes the SEDES EDC system for form entry. If site personnel need access to SEDES for this study, please contact support@nrgoncology.org. SEDES can be accessed via the GOG Web menu. 

 

GOG-0238 and GOG-0258In preparation for final analyses, please submit all overdue forms and address all queries for GOG-0238 and GOG 0258 no later than Friday, November 4, 2022. Both protocols utilize the SEDES EDC system for form entry. If site personnel need access to SEDES for this study, please contact support@nrgoncology.orgSEDES can be accessed via the GOG Web menu. Please bring forms up to date by so analysis can proceed. 

 

GOG-0263: In preparation for a DMC review, please submit all overdue forms and address all queries for GOG-0263 no later than Monday, October 31, 2022. This trial utilizes the SEDES EDC system for form entry. If site personnel need access to SEDES for this study, please contact support@nrgoncology.org. SEDES can be Accessed via the GOG Web menu.

  

5. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, November 9, 2022.

 

NRG Cancer Care Delivery Research (CCDR) Committee Hosts Webinar on Artificial Intelligence

The NRG CCDR Committee will be hosting a webinar to introduce participants to the use of artificial intelligence (AI) and its role in varied cancer care delivery settings. Integration of AI technology into cancer care settings may improve and expedite diagnosis, inform clinical decision making and produce better health outcomes. The presentations will highlight AI’s contribution to radiation oncology, medical oncology and palliative care. This session will held on November 10, 2022, 12 – 1:30pmEST and co-lead by Dr. Julian Hong of the University of California, San Francisco and Dr. Michael Gensheimer of Stanford Health Care. Please view the flyer here.

Click here to register for the webinar


What Do You Need to Know About the NRG-BN010, NRG-HN010, and NRG-GI005 Clinical Trials?

We interviewed Dr. Rupesh Kotecha, Radiation Oncology Chair for the NRG-BN010 trial (on behalf of the Study PI, Dr. Stephen Bagley), and NRG-Head and Neck Cancer Committee Vice Chair, Dr. Stuart Wong on the NRG-HN010 trial (on behalf of the Study PI, Dr. Alan Ho), and Dr. Van Morris, Study PI for NRG-GI005/The COBRA Study. Learn more in the videos below.


NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma https://youtu.be/xMPMd4pz9tQ

 

NRG-HN010: A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer https://youtu.be/DwhJmxkc0Po


NRG-GI005/The COBRA Study: A Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer https://youtu.be/A1XRwtOwVTY


Veterans Day Closure Information

Please note the following NRG Oncology locations will be closed on Friday, November 11, 2022, in observance of Veterans Day: Philadelphia East Operations Center, Buffalo SDMC, and the Biospecimen Bank in San Francisco. All other locations will be open during regular business hours on that day. More information about these closures is posted on the CTSU website.

 

PRESS RELEASES

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

In the NRG Oncology clinical trial NRG-RTOG 1112, which sought to better determine the role of stereotactic body radiation therapy (SBRT) in the treatment of patients with advanced hepatocellular carcinoma (HCC), it was demonstrated that adding SBRT to Sorafenib improved overall survival (OS). These results were presented during the Plenary Session of the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in October 2022. NRG Oncology designed and led this trial which was conducted in the National Clinical Trials Network with funding from the National Cancer Institute, part of the National Institutes of Health. Read the full press release


Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

NRG Oncology investigators analyzed clinical and digital histopathology data from five Phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multi-modal intelligence models (MMAI) that could outperform the National Comprehensive Cancer Network (NCCN) in the prediction of distant metastasis (DM) and other outcomes. MMAI models could, in fact, stratify patients into risk groups that more accurately reflected their prognosis in comparison to NCCN risk groups. These results were presented during the Plenary Session of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2022. Read the full press release

 

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

Results from the analysis of the NRG Oncology RTOG 1005 clinical trial data concluded that treating patients with early-stage, high-risk breast cancer with a supplemental radiation boost to the surgical cavity concurrently during hypo-fractionated whole breast irradiation (H-WBI) for a 3-week treatment course was not considered inferior to treating patients over several weeks with conventional whole breast irradiation (C-WBI) and a sequential boost following lumpectomy. These results were recently presented during the Plenary Session of the American Society for Radiation Oncology (ASTRO) Annual Meeting in October 2022. Read the full press release

 

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional failure (LRF) when compared to RT + cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) that have a contraindication to cisplatin. These findings were presented during the plenary session at American Society for Radiation Oncology (ASTRO) annual meeting held in San Antonio, Texas. This was one of four NRG Oncology papers presented during the 2022 ASTRO plenary session. Read the full press release

 

Toxicity Data Reveal No Safety Concerns with S/N1806 Bladder Cancer Trial

Updated toxicity data from the ongoing SWOG/NRG 1806 clinical trial, which tests combining chemoradiation therapy with immunotherapy in patients with localized muscle-invasive bladder cancer, reveal no significant safety concerns with the combination. Read the full press release

 

 

PUBLICATIONS REMINDERS

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

 

JOURNAL ARTICLES

Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2022 Oct 19: JCO2200164. doi: 10.1200/JCO.22.00164. Epub ahead of print. PMID: 36260832. Read more

 

Please note the following upcoming meeting and abstract submission deadline dates

UPCOMING MEETINGS

Radiological Society of North America (RSNA); Nov 27-Dec 1, 2022; Chicago, IL


San Antonio Breast Cancer Symposium (SABCS); Dec 6-10, 2022; San Antonio, TX


Society for Neuro-Oncology (SNO); Nov 16-20, 2022; Tampa, FL


Society of Urologic Oncology (SUO); Nov 30-Dec 2, 2022; San Diego, CA 

 

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 14-19, 2023; Orlando, FL; due to publications committee Nov 3, 2022; meeting submission deadline Nov 17, 2022, 11:59 ET; LBA Jan 12, 2023


American Head & Neck Society (AHNS); July 8-12, 2023; Montreal, QC Canada; due to publications committee Nov 14, 2022; meeting submission deadline Dec 2, 2022, 5 pm EST


American Society of Clinical Oncology (ASCO) GI; Jan 19-21, 2023; San Francisco, CA; LBA Nov 15, 2022, NOON (EST)


American Society of Clinical Oncology (ASCO) GU; Feb 16-18, 2023; San Francisco, CA; LBA Dec 13, 2022, NOON (EST)


ESMO Gynaecological Cancers Annual Congress 2023; Feb 23-24, 2023; Barcelona, Spain; due to publications committee Nov 15, 2022; meeting submission deadline Nov 29, 2022, TIP 9 pm CET (CntEurTime)


European Society for Radiotherapy and Oncology (ESTRO); May 12-16, 2023; Vienna, Austria; LBA Jan 18, 2023, 9:00 pm


Society for Clinical Trials (SCT); May 21-24, 2023; Baltimore, MD; Contributed Oral & Poster Presentations due to publications committee Oct 31, 2022; meeting submission deadline Nov 14, 2022


Society of Surgical Oncology (SSO 2023); Surgical Cancer Care; Mar 22-25, 2023; Boston, MA; LBA Dec 9, 2022


St. Gallen Breast Cancer Conference (SG-BCC); Mar 15-18, 2023; Vienna, Austria; due to publications committee Dec 2, 2022; meeting submission deadline Dec 16, 2022

Facebook  Twitter  Instagram  LinkedIn